NCT04233918View on ClinicalTrials.gov

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

May 30, 2023

Conditions

Homozygous Familial Hypercholesterolemia

Interventions

DRUG

Evinacumab

Part A: Single IV dose Part B \& C: IV dose Q4W

Trial Locations (11)

1090

Regeneron Research Site, Vienna

2145

Regeneron Research Center, Westmead

11217

Regeneron Research Center, Taipei

19106

Regeneron Research Center, Philadelphia

19803

Regeneron Research Site, Wilmington

33434

Regeneron Research Site, Boca Raton

66190

Regeneron Research Site, Kansas City

84108

Regeneron Research Center, Salt Lake City

02115

Regeneron Research Center, Boston

1105 AZ

Regeneron Research Site, Amsterdam

04209

Regeneron Research Site, Kyiv

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04233918 - Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia | Biotech Hunter | Biotech Hunter